
MSD to cut 148 jobs at Pennsylvania plant
pharmafile | August 16, 2016 | News story | Manufacturing and Production, Research and Development | MSD, job cuts, zontivity
MSD is due to cut 148 jobs at its North Wales, Pennsylvania campus effective September 12, according to the company’s Worker Adjustment and Retraining Notification filed with the State Department.
Spokeswoman Lainie Keller remarked that the decision is a result of the company’s move to cease production of its heart drug Zontivity after September 2, meaning that field-based team members and other HQ-based roles will be displaced.
The move is separate from the company’s reduction of 300 jobs from its Montgomery County site and a pair of its facilities from New Jersey to Massachusetts to enable earlier access to emerging external research and technologies. MSD continues to employ more than 12,000 workers in Montgomery County.
Matt Fellows
Related Content

Merck and Daiichi Sankyo expand development and commericalisation agreement to include MK-6070
Daiichi Sankyo and Merck (known as MSD outside of the US and Canada) have announced …

Merck shares data from phase 3 trial of Keytruda for gastric cancers
Merck, known as MSD outside of the US and Canada, has announced data from the …

Merck to acquire Harpoon Therapeutics for approximately $680m
Merck (known as MSD outside of the US and Canada) and Harpoon Therapeutics have announced …






